학술논문
Expression of miR-223 to predict outcomes after transcatheter aortic valve implantation.
Document Type
Academic Journal
Author
Eyileten C; Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland.; Skrobucha A; 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.; Starczyński M; 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.; Boszko M; 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.; Jarosz-Popek J; Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland.; Fitas A; Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland.; Filipiak KJ; Department of Clinical Sciences, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.; Kochman J; 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.; Huczek Z; 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.; Rymuza B; 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.; Wilimski R; Department of Cardiac Surgery, Medical University of Warsaw, Poland. radoslaw.wilimski@wum.edu.pl.; Kuśmierczyk M; Department of Cardiac Surgery, Medical University of Warsaw, Poland.; Siller-Matula JM; Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland.; Department of Cardiology, Medical University of Vienna, Austria.; Postula M; Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland.; Gąsecka A; 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.
Source
Publisher: Via Medica Country of Publication: Poland NLM ID: 101392712 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1898-018X (Electronic) Linking ISSN: 1898018X NLM ISO Abbreviation: Cardiol J Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment for aortic stenosis (AS) in patients at increased surgical risk. Up to 29% of patients annually experience major adverse cardiac and cerebrovascular events (MACCE) after TAVI. MicroRNAs (miRNA) are currently widely investigated as novel cardiovascular biomarkers. The aim of this study was to determine the influence of TAVI on the expressions of selected miRNAs associated with platelet function (miR-125a-5p, miR-125b and miR-223), and evaluate the predictive value of these miRNAs for MACCE in 65 patients undergoing TAVI.
Methods: Venous blood samples for miRNA expression analysis were collected 1 day before TAVI and at hospital discharge. The expression of miR-223, miR-125a-5p, miR-125b was evaluated in platelet-depleted plasma.
Results: The expression of miR-223 and miR-125b increased after TAVI, compared to the measurement before (p = 0.020, p = 0.003, respectively). Among 63 patients discharged from the hospital, 18 patients experienced MACCE (29%) during the median 15 months of observation. Baseline low miR-223 expression was a predictor of MACCE in univariate Cox regression analysis (hazard ratio [HR]: 2.71, 95% confidence interval [CI]: 1.04-7.01; p = 0.041). After inclusion of covariates, age, gender (male), New York Heart Association class and diabetes into the multivariate Cox regression model, miR-223 did not reach statistical significance (HR: 2.56, 95% CI: 0.79-8.33; p = 0.118).
Conclusions: To conclude, miR-223 might improve risk stratification after TAVI. Further studies are required to confirm the clinical applicability of this promising biomarker.
Methods: Venous blood samples for miRNA expression analysis were collected 1 day before TAVI and at hospital discharge. The expression of miR-223, miR-125a-5p, miR-125b was evaluated in platelet-depleted plasma.
Results: The expression of miR-223 and miR-125b increased after TAVI, compared to the measurement before (p = 0.020, p = 0.003, respectively). Among 63 patients discharged from the hospital, 18 patients experienced MACCE (29%) during the median 15 months of observation. Baseline low miR-223 expression was a predictor of MACCE in univariate Cox regression analysis (hazard ratio [HR]: 2.71, 95% confidence interval [CI]: 1.04-7.01; p = 0.041). After inclusion of covariates, age, gender (male), New York Heart Association class and diabetes into the multivariate Cox regression model, miR-223 did not reach statistical significance (HR: 2.56, 95% CI: 0.79-8.33; p = 0.118).
Conclusions: To conclude, miR-223 might improve risk stratification after TAVI. Further studies are required to confirm the clinical applicability of this promising biomarker.